Brain 'Firmness' test may spot Alzheimer's early
NCT ID NCT06029114
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
Researchers at Mayo Clinic are testing whether measuring brain stiffness with a special MRI scan (magnetic resonance elastography) can serve as a new biomarker for Alzheimer's disease. The study will enroll 450 adults, including healthy volunteers, people with mild cognitive impairment, and those with Alzheimer's. Participants undergo a brain scan that measures tissue stiffness, which may change with disease progression.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Magnetic Resonance Elastography (MRE) scan
- What this could lead to
- If successful, this could lead to a new, non-invasive way to detect Alzheimer's disease earlier using a simple MRI-based scan.
- What could go wrong
- This is an observational study, not a treatment trial. Brain stiffness may not prove to be a reliable or practical biomarker for routine diagnosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 450 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects will be selected from Mayo Alzheimer's Disease Research Center.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for Control Subjects: * In good general health * No Active neurological or psychiatric conditions, if a prior neurological or psychiatric condition was present they must have returned to normal * No cognitive complaints * Normal neurological examination * No psychoactive medications * They may have a chronic medical condition that does not affect cognition * Low Aβ load Pittsburgh compound-B (PiB) ratio \<1.5 Inclusion Criteria for Mild Cognitive Impairment Subjects: * In good general health * Memory complaint documented by the patient and collateral source * Normal general cognitive function as determined by measure of general intellectual function and screening including the Short Test of Mental Status * Normal activities of daily living as documented by history and Record of Independent Living * Not demented by DSM-III-R criteria * Do have an objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists * High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5 Inclusion Criteria for Alzheimer's Disease Subjects: * In good general health * Dementia not a result of other medical or psychiatric conditions * Diagnosis of dementia made according to DSM-III-R criteria * Do have objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists * High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5 Exclusion Criteria: * Alzheimer's disease or mild cognitive impairment due to a known genetic mutation * Major depression * History of primary or metastatic intracranial neoplasm, significant head trauma, intra-cerebral hemorrhage, hemispheric stroke * Contradictions to MRI imaging including but not limited to cardiac pacemakers, intraocular or intracranial metal, or other MRI incompatible devices. * Pregnant women. Women of child bearing potential will be given a urine pregnancy test prior the MRI scan. Results will be shared with the participant. If the pregnancy test is positive, the participant will not be included within the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Can a gentle electric current calm the mind in Alzheimer's?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier